Standards for the Interoperable Exchange of Information for Tracing of Human, Finished, Prescription Drugs, in Paper or Electronic Format; Establishment of a Public Docket

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; establishment of docket; request for comments.

SUMMARY: The Food and Drug Administration (FDA) is establishing a public docket to receive information and comments on standards for the interoperable exchange of information associated with transactions involving human prescription drugs in a finished dosage form (prescription drugs) to comply with new requirements in the Drug Supply Chain Security Act (DSCSA). We are seeking information from drug manufacturers, repackers, wholesale distributors, dispensers (primarily pharmacies) and other drug supply chain stakeholders and interested parties, including standards organizations, State and Federal Agencies, and solution providers. In particular, stakeholders and other interested parties are requested to comment about the interoperable exchange of transaction information, transaction history, and transaction statements, in paper or electronic format, for each transfer of product in which a change of ownership occurs. This action is related to FDA’s implementation of the DSCSA.

DATES: Submit either electronic or written comments by [INSERT DATE 60 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER].

ADDRESSES: Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration,
I. Background

On November 27, 2013, the DSCSA (Title II, Pub. L. 113-54) was signed into law. The DSCSA outlines critical steps to build an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed within the United States. Section 202 of the DSCSA, which adds section 582 to the Federal Food, Drug, and Cosmetic Act (FD&C Act), directs the Secretary of Health and Human Services (the Secretary) to establish standards for the interoperable exchange of transaction information, transaction history, and transaction statements, in paper or electronic format, in consultation with other appropriate Federal officials, manufacturers, repackagers, wholesale drug distributors, dispensers, and other pharmaceutical distribution supply chain stakeholders.

FDA has been engaged in efforts to improve the security of the drug supply chain for many years to protect U.S. patients from unsafe, ineffective, and poor quality drugs. Since the formation of the first FDA Counterfeit Drug Task Force in 2003, FDA has strongly advocated for a multilayered approach to securing the supply chain and protecting consumers from the threats posed by counterfeit and diverted drugs. The ability to track and trace finished prescription drugs plays a significant role in providing transparency and accountability in the drug supply chain. Under section 505D of the FD&C Act (21 U.S.C. 355e), FDA has been
evaluating existing and emerging standards, system attributes and needs, and adoption of track
and trace and authentication systems and technology. The system that will be established under
DSCSA will enhance FDA’s ability to help protect U.S. consumers from exposure to drugs that
may be counterfeit, stolen, contaminated, or otherwise harmful by improving detection and
removal of potentially dangerous drugs from the drug supply chain.

FDA is announcing the establishment of a public docket to provide an opportunity for
interested persons to share information, current practices, research, and ideas on the feasibility of
establishing standardized documentation to be used by members of the pharmaceutical
distribution supply chain to convey the transaction information, transaction history, and
transaction statement to the subsequent purchaser of a product and to facilitate the exchange of
lot level data.

II. Definitions

The following definitions for transaction information, transaction history, and transaction
statement as defined under the DSCSA are provided to assist stakeholders in developing
comments or responses. In addition, FDA is interested in learning about practices, processes,
and systems that supply chain stakeholders currently use to exchange information, such as
product information, information related to the sale or change of ownership of prescription
drugs, or communications about drugs in distribution. For other definitions, please refer to
section 202 of DSCSA.

Under DSCSA, “transaction information” means (A) the proprietary or established name
or names of the product; (B) the strength and dosage form of the product; (C) the National Drug
Code number of the product; (D) the container size; (E) the number of containers; (F) the lot
number of the product; (G) the date of the transaction; (H) the date of shipment, if more than 24
hours after the date of transaction); (I) the business name and address of the person from whom
ownership in being transferred; and (J) the business name and address of the person to whom
ownership is being transferred. “Transaction history” means a statement in paper or electronic
form, including the transaction information for each prior transaction going back to the
manufacturer of the product. “Transaction statement” is a statement, in paper or electronic form,
that the entity transferring ownership in a transaction--(A) is authorized as required under the
DSCSA; (B) received the product from a person that is authorized as required under the DSCSA;
(C) received transaction information and a transaction statement from the prior owner of the
product, as required under section 582 [of the DSCSA]; (D) did not knowingly ship a suspect or
illegitimate product; (E) had systems and processes in place to comply with verification
requirements under section 582 [of the DSCSA]; (F) did not knowingly provide false transaction
information; and (G) did not knowingly alter the transaction history.

III. Request for Comments and Information

FDA is requesting comments and supporting information on the following: (1) Current
practices and ideas that may be used for the interoperable exchange of transaction information,
transaction history, and transaction statements, in paper or electronic format, for each transfer of
product in which a change of ownership occurs (i.e., transaction); (2) the feasibility of
establishing standardized documentation to be used by members of the pharmaceutical
distribution supply chain to convey the transaction information, transaction history, and
transaction statement to the subsequent purchaser of a product and to facilitate the exchange of
lot level data; and (3) current practices and ideas that may be used for the exchange of
information between members of the pharmaceutical distribution supply chain and FDA to
provide, receive, and terminate notifications, respond to requests for verification of product, and
respond to requests for information from FDA or other appropriate Federal or State officials in
the event of a recall or for the purpose of investigating a suspect or illegitimate product.

To facilitate this discussion, FDA has included several questions in the following
paragraphs. These questions, which are not meant to be exhaustive, are provided to stimulate
public comments that will help FDA establish initial standards for the interoperable exchange of
information for tracing of prescription drugs in paper or electronic format. The public is
encouraged to address these and/or other related issues.

Questions related to (1) current practices and suggestions for the interoperable exchange of
transaction information, transaction history, and transaction statements and (2) the feasibility of
establishing standardized documentation to be used by members of the pharmaceutical
distribution supply chain to convey the transaction information, transaction history, and
transaction statement to the subsequent purchaser of prescription drugs and to facilitate the
exchange of lot level data:

1. What types of information about transactions do you exchange? What practices,
processes, or systems, either paper-based or electronic, do supply chain stakeholders use
to exchange this information? Are the practices, processes, or systems based on a
standard? Are they interoperable with other systems that supply chain stakeholders may
be using?

2. What practices, processes or systems, either paper-based or electronic, do supply chain
stakeholders use to exchange information related to prior transactions? Are the practices,
processes, or systems based on a standard? Are they interoperable with other systems
that supply chain stakeholders may be using?
3. Do the practices, processes, or systems that supply chain stakeholders use to exchange transaction information or transaction histories include or have the ability to include lot level data?

4. If you are currently using paper means to exchange transaction information or history, when do you plan to move to an electronic format?

5. Are there challenges to adopting and using a system, in paper or electronic format, for the interoperable exchange of transaction information or history? How can these challenges be addressed?

6. Are there practices, processes, or systems that supply chain stakeholders can use now to exchange the information in the transaction statement required by the DSCSA?

7. Are there challenges to providing the transaction statement to supply chain stakeholders in either paper or electronic form? How can these challenges be addressed?

8. Are there standards or current practices that you would recommend for FDA to consider as a model for providing any or all of the transaction information, transaction history, or transaction statement to other supply chain stakeholders?

9. Are there other technologies, systems, or solutions available now that would enable the interoperable exchange of transaction information, transaction history, or transaction statements?

Questions related to (3) current practices and suggestions for the exchange of information between supply chain stakeholders or with FDA to provide, receive, and terminate notifications, respond to requests for verification of suspect product, and respond to requests for information from FDA or other appropriate Federal or State officials in the event of a recall or for the purpose of investigating a suspect or illegitimate product:
10. Are there current practices, processes, or systems that could be used to exchange information between supply chain stakeholders and FDA with respect to providing, receiving, and terminating a notification that an illegitimate product is found in distribution? Are these practices, processes, or systems effective? If not, please provide recommendations to improve these practices, processes, or systems.

11. Are there current practices, processes, or systems that could be used to exchange information between supply chain stakeholders or with FDA to respond to requests to verify the lot number, expiration date, and other indices of identity assigned to a product by the manufacturer or repackager (i.e., requests for verification of suspect product)? Are these practices, processes, or systems effective? If not, please provide recommendations to improve these practices, processes, or systems.

12. Are there current practices, processes, or systems that could be used for providing information in response to requests from FDA or other appropriate Federal or State officials in the event of a recall or for the purpose of investigating a suspect or illegitimate product? Are these practices, processes, or systems effective? If not, please provide recommendations to improve these practices, processes, or systems.

Question related to capturing information that has not necessarily been addressed by the previous questions:

13. Are there other considerations related to standards for the interoperable exchange of information for tracing of human, finished, prescription drugs that have not been addressed by the previous questions? Please provide any additional information that you think could be helpful for the Agency to consider as it implements these provisions of the DSCSA.
III. Submission of Comments

Interested persons may submit either electronic comments regarding this document to http://www.regulations.gov or written comments to the Division of Dockets Management (see ADDRESSES). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at http://www.regulations.gov.


Leslie Kux,
Assistant Commissioner for Policy.

[FR Doc. 2014-03592 Filed 02/19/2014 at 8:45 am; Publication Date: 02/20/2014]